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Dopamine (DA) modulates spinal reflexes, including nociceptive reflexes, in part via the
D3 receptor subtype. We have previously shown that mice lacking the functional D3
receptor (D3KO) exhibit decreased paw withdrawal latencies from painful thermal stimuli.
Altering the DA system in the CNS, including D1 and D3 receptor systems, reduces the
ability of opioids to provide analgesia. Here, we tested if the increased pain sensitivity
in D3KO might result from a modified μ-opioid receptor (MOR) function at the spinal
cord level. As D1 and D3 receptor subtypes have competing cellular effects and can
form heterodimers, we tested if the changes in MOR function may be mediated in D3KO
through the functionally intact D1 receptor system. We assessed thermal paw withdrawal
latencies in D3KO and wild type (WT) mice before and after systemic treatment with
morphine, determined MOR and phosphorylated MOR (p-MOR) protein expression levels
in lumbar spinal cords, and tested the functional effects of DA and MOR receptor agonists
in the isolated spinal cord. In vivo, a single morphine administration (2mg/kg) increased
withdrawal latencies in WT but not D3KO, and these differential effects were mimicked
in vitro, where morphine modulated spinal reflex amplitudes (SRAs) in WT but not D3KO.
Total MOR protein expression levels were similar between WT and D3KO, but the ratio of
pMOR/total MOR was higher in D3KO. Blocking D3 receptors in the isolated WT cord
precluded morphine’s inhibitory effects observed under control conditions. Lastly, we
observed an increase in D1 receptor protein expression in the lumbar spinal cord of D3KO.
Our data suggest that the D3 receptor modulates the MOR system in the spinal cord, and
that a dysfunction of the D3 receptor can induce a morphine-resistant state. We propose
that the D3KO mouse may serve as a model to study the onset of morphine resistance at
the spinal cord level, the primary processing site of the nociceptive pathway.
Keywords: dopamine d3 receptor, mu-opiod receptor, nociception, second messenger cross-talk, dopamine d1
recptor, spinal reflexes
INTRODUCTION
Opiate analgesics are the classical first line treatment for strong
and persistent pain, but their effectiveness in long-term treatment
is limited by the emergence of tolerance (Colpaert, 2002; Dupen
et al., 2007; Bekhit, 2010; Joseph et al., 2010). This morphine-
resistant condition is thought to arise over time and involve a
dysfunction of μ-opioid receptor (MOR)- and dopamine (DA)-
receptor mediated cAMP/PKA second messenger pathways in the
brain (Suzuki et al., 2001; Schmidt et al., 2002; Fazli-Tabaei et al.,
2006; Zhang et al., 2008, 2012; Le Marec et al., 2011; Enoksson
et al., 2012). However, under this tenet the role of the spinal
cord remains overlooked. The spinal cord is the first site for the
processing for nociceptive information, and it houses both DA
and MOR receptors in the dorsal horn (Abbadie et al., 2001;
Levant and McCarson, 2001; Ray and Wadhwa, 2004; Zhu et al.,
2007, 2008). DA regulates spinal cord circuits, including pain-
associated responses (Garraway and Hochman, 2001; Clemens
and Hochman, 2004; Yang et al., 2005; Keeler et al., 2012), and
both D1 and D3 receptors are present in the dorsal horn (Levant
and McCarson, 2001; Zhu et al., 2007). Further, the MOR is asso-
ciated with inhibitory G proteins (Gi and Go) and is present in the
spinal cord (Mansour et al., 1994; Ji et al., 1995; Ray andWadhwa,
1999, 2004; Abbadie et al., 2001, 2002; Zhang et al., 2006). Upon
ligand binding to the receptor, signaling cascades are activated
that inhibit cAMP production, resulting in the opening of K+
channels or closing of Ca2+ channels (Connor and Christie, 1999;
Connor et al., 1999; Williams et al., 2001). Its desensitization is
under the control of G-protein-coupled receptor kinase (GRK)-
mediated phosphorylation (Connor et al., 2004; Gainetdinov
et al., 2004; Garzon et al., 2005), followed by ß-arrestin-mediated
internalization (Bohn et al., 1999, 2000; Ohsawa et al., 2003;
Connor et al., 2004). Blocking ß-arrestin expression improves
morphine-mediated analgesia (Li et al., 2009), and recent data
suggest that morphine-induced ß-arrestin complex formation
primarily requires D1 receptors (Urs et al., 2011).
Interestingly, D1 receptors form heterodimers with D3 recep-
tors (Surmeier et al., 1996; Fiorentini et al., 2008; Maggio et al.,
2009; Missale et al., 2010; Cruz-Trujillo et al., 2013) and both
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play a role in opioid tolerance (Lin et al., 1996; Cook et al., 2000;
Richtand et al., 2000; Fazli-Tabaei et al., 2006). We recently found
that animals lacking a functional D3 receptor (D3KO) exhibited
facilitated pain-associated reflexes (Keeler et al., 2012), and we
address here the role of the spinal D3 receptor onMOR functional
states and morphine responsiveness.
We evaluated thermal pain paw withdrawal latencies in D3KO
and wild type (WT) controls before and after administration of
morphine, determined naïve MOR and phosphorylatedMOR (p-
MOR) protein expression levels in the lumbar spinal cord, and
compared spinal reflex amplitudes (SRA) in isolated spinal cords
from WT and D3KO in vitro, to assess the role of the D3 receptor
in mediating morphine actions in isolated WT spinal cords.
We found that naïve D3KO were unresponsive to morphine
administration, both in vivo and in vitro, and that this lack
of responsiveness was associated with increased levels of spinal
pMOR in D3KO. Moreover, while the highly-specific MOR ago-
nist, DAMGO, was able to decrease SRAs in both WT and D3KO
in vitro, this effect was significantly smaller in D3KO than WT.
Finally, acute pharmacological block of the D3 receptor in the
isolated WT cord was sufficient to induce a D3KO-like pheno-
type and prevent the modulatory actions of morphine on SRAs
observed under control conditions.
MATERIALS AND METHODS
All experimental procedures complied with NIH guidelines
for animal care and were approved by the East Carolina
University Institutional Animal Care and Use Committee. Male
dopamine D3 receptor knockout mice (D3KO; strain B6.129S4-
Drd3tm1dac/J; stock # 002958, Jackson Laboratory, Bar Harbor,
ME) and their appropriate associated wild-type (WT) controls
(C57BL/6) were used for in vivo behavioral testing and Western
blot experiments (3–4 months), while neonatal pups of either sex
were used for extracellular electrophysiology and pharmacology
(postnatal days 7–14).
BEHAVIORAL ASSESSMENTS
Thermal withdrawal latencies were tested on 10 D3KO and 8
WT males using a Hargreaves apparatus. Prior to baseline test-
ing, mice were acclimated to the apparatus by being placed in the
apparatus for 2 h per day for a total of 5 days. Baseline thresh-
olds were obtained over three test sessions, with each test session
occurring at the same time of day, and each mouse being placed
in the chamber to which it was acclimated. Each test session con-
sisted of three trials (i.e., application of the heat stimulus at 56◦C)
separated by at least 5min. The latencies obtained over the 3 tri-
als were averaged to get the mean baseline latency for each test
day. After baselines were established, a randomly chosen subset
of mice (5 D3KO and 4 WT) was administered morphine sulfate
(Sigma, 2mg/kg, i.p.) and tested 30min later as outlined above.
TISSUE COLLECTION ANDWESTERN BLOT ANALYSIS
One week after behavioral testing, animals were deeply anes-
thetized with inhaled isoflurane (4–5%), decapitated, and spinal
cords were dissected, frozen in liquid nitrogen and stored at
-80◦C. Proteins were homogenized in RIPA buffer containing
protease and phosphatase inhibitors (Sigma-Aldrich, St. Lois,
MO), lysates centrifuged, and the supernatant collected. Total
protein was quantified using an EZQ Quantitation Kit (R33200;
Invitrogen, Grand Island, NY). Equal concentrations of protein
were separated using a SDS-PAGE (Criterion TGX Any kD, Bio-
Rad, Canton, MA) and transferred onto a PVDF membrane
(Immobolin-P, Millipore, Germany). To verify consistent protein
transfer across the lanes, we measured total protein staining of the
membrane with Coomassie Blue, and compared the protein stain-
ing with the β-actin expression in the corresponding lanes.We did
not observe any significant difference in β-actin protein expres-
sion betweenWT and D3KO (p = 0.54 and 0.2, respectively). For
MOR and pMOR protein expression assessments, membranes
were blocked using 5% BSA overnight and probed with primary
antibodies for the MOR (ab10275, Abcam, UK) at 1:1000 and
p-MOR (bs3724R, BIOSS, UK) at 1:1000 overnight. This MOR
antibody can detect bands at ∼50 kDa (Kerros et al., 2010) and
has been verified in a different study by comparing it to the effects
of another MOR antibody (Loyd et al., 2008). The pMOR anti-
body we used shows a strong band at ∼44 kDa (http://biossusa.
com/store/bs-3724r.html), and control ELISA data provided by
BIOSS show an increased binding of this antibody to pMOR
over MOR (data not shown, BIOSS, personal communication).
Membranes were washed and incubated in anti-mouse and anti-
rabbit secondary antibodies (R&D Systems, Minneapolis, MN)
respectively. Target proteins were visualized using ECL Plus detec-
tion reagent (80916; Invitrogen, Grand Island, NY) according to
the manufacturer’s recommendations, quantified using relative
integrated density normalized against β-actin (ab8226, Abcam,
UK) at 1:2000, and analyzed with ImageJ software (version 1.48S,
NIH). Expression values are given as the ratio of MOR or pMOR
to β-actin.
For D1 receptor protein assessments, membranes were blocked
overnight using 5% BSA at 4◦C and probed with primary anti-
bodies for the D1 receptor (ab81296, Abcam, Cambridge, MA)
and β-actin (ab8226, Abcam, UK) at 1:1000 overnight. This D1
receptor antibody can detect bands at both 50 and 75 kDa (Mizuta
et al., 2013). Membranes were washed four times at 5min in TBS-
T and incubated for 30min at room temperature using 5% BSA
in anti-rabbit IR800 (35571, Thermo Scientific, Rockford, IL) and
anti-mouse IR680 (926-68070, Li-Cor, Lincoln, NE) secondary
antibodies at 1:30000. The membranes were then washed another
three times for 5min in TBS-T followed by two washes at 5min
in PBS. Target proteins were visualized using the Li-Cor detec-
tion system (Odyssey Clx, Li-Cor Biosciences, Lincoln, NE) and
associated software (Image Studio, Li-Cor), and quantified with
ImageJ. D1 receptor protein expression values were normalized
to β-actin protein expression.
ELECTROPHYSIOLOGY AND PHARMACOLOGY
A total of 19 WT and 17 D3KO neonatal pups of either sex
(postnatal days 7–14) were used for extracellular electrophysi-
ological and pharmacological experiments. As reported earlier
(Clemens and Hochman, 2004; Keeler et al., 2012), animals were
deeply anesthetized with i.p. injection (50μl/10 g) of a ketamine
(90mg/ml)/xylazine (10mg/ml) mix, and after verification of
deep anesthesia decapitated. Spinal cords were removed quickly,
usually completed within 10min, placed in a Sylgard-lined Petri
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dish, the Dura mater desheathed and the cords hemisected.
Throughout this process the preparations were submersed in
oxygenated (95 O2/5% CO2) ice-cold high-sucrose artificial cere-
brospinal fluid (containing in mM: 342 sucrose, 180.2 Glucose,
203.3 MgCl2, 147.02 CaCl2, 137.99 NaH2PO4, 84.01 NaHCO3,
74.56 KCl, pH 7.4). After these initial dissection steps, the high-
sucrose solution replaced with oxygenated artificial cerebrospinal
fluid (ACSF; containing in mM: 128NaCl, 1.9 KCl, 10 Glucose,
1.3MgSO4, 2.4 CaCl2, 1.2 KH2PO4, 26NaHCO3, pH 7.4), accli-
mated to room temperature. Subsequently, small glass suction
electrodes were carefully attached to identified dorsal and ventral
lumbar roots (usually L2-L5).
After a recovery of phase of ∼30–60min, reflex responses
were elicited with a constant current stimulator (Iso-Stim 01D,
NPI Electronics, Tamm, Germany, or a custom-built Linear
Isolation Unit, Model MI 401, Department of Animal Physiology,
University of Cologne) with pulses of 100–500μA for 100–
250μs. Signals were recorded and amplified with a 4-channel
differential AC amplifier (Model 1700, A-M Systems, Sequim,
WA), digitized with a Digidata 1440A, and analyzed with pClamp
v.10.2 software (Molecular Devices, Sunnyvale, CA). Single pulse
stimulations were delivered every 60 s (WT) or 120–180 s (D3KO)
to avoid habituation (data not shown). Reflex responses were
recorded and analyzed by rectified integration of the recorded
responses. SRAs were obtained before (control conditions) and
during application of morphine sulfate (Sigma, 1μM), the D3
receptor-preferring antagonist, nafadotride (Tocris, 20μM), or
the specific MOR agonist DAMGO (Tocris, 10μM). For test-
ing the interactions between the D3 and MOR in the WT spinal
cord, we first bath-applied the D3-receptor preferring antago-
nist, nafadotride, to establish the effects of this drug, before
adding morphine to the bath. Drugs were bath-applied and for
30–60min, during which time the stimulus protocol was main-
tained. Following the drug application testing, drugs were care-
fully washed out (through ACSF exchange of 4–5 times the bath
volume). For analytical purposes, we compared the last 10 consec-
utive SRAs in the control condition with the last 10 SRAs during
the drug application.
STATISTICAL ANALYSIS
For behavioral experiments, baseline and post-morphine thermal
thresholds were compared between WT and D3KO mice using
a RM ANOVA (SigmaPlot, Systat, San Jose, CA) with p < 0.05
indicating significance. For determining differences in MOR and
p-MOR protein expression levels between groups, we used using
a paired t-test (JMP v.10, SAS, Inc., Cary NC) with p < 0.05
indicating significance. For electrophysiological experiments,
SRAs under drug conditions were averaged and normalized to
the mean of the pre-drug values, and statistical significance was
determined with t-tests or ANOVA and subsequent post-hoc
comparisons, as appropriate, and with α set <0.05 (SigmaPlot,
Systat, San Jose, CA).
RESULTS
BEHAVIOR
Under baseline conditions, pain withdrawal latencies of WT were
significantly higher than those of D3KO (WT: 6.24 ± 0.64,
n = 4; D3KO: 4.84 ± 1.08 s, p < 0.001, n = 5, t-test, Figure 1,
left panel), suggesting an increased excitability to thermal stim-
ulation of the hindpaw in the D3KO animals. A single injection
of morphine (2mg/kg, i.p.) significantly increased thermal with-
drawal latencies in WT from 6.24 ± 0.64 s to 11.01 ± 1.91 s
(p < 0.001, Figure 1, right panel), whereas they remained unal-
tered in D3KO (4.84 ± 1.08 s, vs. 3.94 ± 0.95, p = 0.902,
RM-ANOVA). Consequently, the difference in pain withdrawal
latencies betweenmorphine-treatedWT andD3KO remained sig-
nificant (p < 0.001, t-test). These data suggest that under naïve
conditions D3KO are unresponsive to the system-wide applica-
tion of morphine.
MOR PROTEIN EXPRESSION IN THE LUMBAR CORD
To test if changes in MOR levels or phosphorylation status might
underlie the lack of the opioid effect observed in D3KO, we
assessed MOR and pMOR protein expression levels in lumbar
spinal cords of WT and D3KO (Figure 2). We probed lumbar
spinal cords of 4 naïve (untreated) WT and 4 D3KO for MOR
(Figure 2A) and pMOR protein expression (Figure 2B). In both
experiments, we first probed for the respective receptor protein
expression before stripping the blot and then probing for ß-actin.
We found that, after normalization to ß-actin, WT and D3KO
had similar levels of total MOR (WT: 1.08 ± 0.32 a.u.; D3KO:
1.146 ± 0.08 a.u., p = 0.85, n = 4; Figure 2C, left panels). In
contrast, pMOR protein expression levels of pMOR in D3KO
were significantly elevated over WT (WT: 0.127 ± 0.03 a.u.,
D3KO: 0.992 ± 0.13 a.u., p < 0.001; Figure 2C, p < 0.01, right
panels). As overall MOR but not pMOR expression levels were
similar, and both sample groups passed Normality (Shapiro-Wilk;
p = 0.441 and p = 0.509, respectively) and Equal Variance Tests
(p = 0.085 and p = 0.505, respectively), we next calculated the
ratio of pMOR to MOR expression levels (Figure 2D). We found
that in WT 36.7 ± 10.6% of total MOR was phosphorylated,
FIGURE 1 | Thermal pain withdrawal latencies at baseline and after a
single i.p. application of 2mg/kg morphine. Left panel: Baseline data for
WT (n = 8) and D3KO (n = 10). Under control conditions, D3KO displayed a
significantly lower time to withdrawal than WT. Right panel: D3KO (n = 5)
continued to maintain a lower withdrawal time than WT (n = 4), but
morphine significantly increased latencies in WT but not D3KO. ∗ indicates
p < 0.001.
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FIGURE 2 | Protein expression levels of total MOR and pMOR in lumbar
spinal cord, normalized to β-actin. (A) Total MOR protein expression in WT
and D3KO (top panels), and their respective ß-actin protein expressions
(bottom panels). Lanes 1–4 represent lumbar spinal cords from four
independent WT, while lanes 5–8 represent tissues from four independent
D3KO. Total MOR protein expression levels were overall similar between WT
and D3KO. Note that we first probed for MOR expression before stripping
and re-probing for ß-actin. (B) pMOR protein expression levels in WT and
D3KO (top lanes), and their respective ß-actin protein expression (bottom
panels). Note that pMOR expression levels showed a stronger labeling in
D3KO than WT. (C) Quantification of expression data: After normalization of
MOR and pMOR data to their respective ß-actin expression in each lane, total
MOR protein expression was similar between WT and D3KO (∗p = 0.85,
n = 4 each). In contrast, pMOR protein expression was significantly
increased in D3KO over WT (p < 0.001, n = 4 each). (D) Ratio of pMOR/MOR
protein expression in the lumbar spinal cord of WT and D3KO. In WT, pMOR
was low, whereas in D3KO a large majority of MORs was phosphorylated
(∗p = 0.008, n = 4 each).
while in D3KO this rate 87.8 ± 7.6% (p = 0.008), suggesting a
reduced availability of the MOR for ligand binding in D3KO.
EXTRACELLULAR ELECTROPHYSIOLOGY AND PHARMACOLOGY
To test the functional effects of morphine mediated responses at
the spinal cord level alone, we next elicited and recorded SRAs
in isolated spinal cords of WT and D3KO before and during
exogenous application of morphine (Figure 3). Constant-current
stimulation of dorsal lumbar roots via glass suction electrodes
elicited within a few milliseconds a monosynaptic stretch reflex
on the corresponding ventral roots (MSR, Figure 3A1) that gen-
erally lasted less than 5–6ms. The signal traces in the MSR time
window were rectified and integrated, and the resulting data
points at the end of each sweep were used as a measure of SRA
(Figure 3A2).
Bath-application of morphine (1μM) induced in WT a grad-
ual decrease in SRA amplitude (Figure 3B1), and led to a
significant reduction inWT SRAs at the end of the recorded appli-
cation interval, from 100.3 ± 0.2 to 75.2 ± 6.8% (p = 0.004,
n = 6, Figure 3B2). In contrast, in D3KO, bath-application of
1μM morphine had no significant modulatory effect on SRA
(Figures 3C1,C2; control: 99.8 ± 0.2%; morphine: 93.2 ± 4.2%,
p = 0.052, n = 12). These data mirror the effects observed in
the thermal pain paradigm, and they suggest that the behavioral
changes observed in the intact animals stem from changes in the
D3 receptor system at the spinal cord level.
While preferentially targeting MORs, morphine activates ∂
and κ receptors as well. To test if a targeted activation of the MOR
pathway alone can mimic the effects observed with morphine, we
bath-applied the MOR-preferring agonist, DAMGO (10μM), to
isolated WT and D3KO spinal cord preparations and assessed its
role in modulating SRAs (Figure 4). In WT, DAMGO decreased
SRAs from 99.9 ± 0.1 to 66.6 ± 4.5% (n = 15, p < 0.001,
Figure 4A), and it decreased them in D3KO from 100 ± 0.15 to
80.9 ± 3.4% (n = 8, Figure 4B). Importantly, the difference in
DAMGO-mediated actions between WT and D3KO was signifi-
cant (p = 0.013). These data suggest that in isolated spinal cords
of D3KO, MORs are still functionally active and can be recruited
by a highly specific agonist, albeit at a smaller magnitude than
in WT.
The D3KO animal is a functional, global knockout, and
consequently D3 receptor function is compromised in every
tissue. To test if D3 receptor dysfunction in the spinal cord
is sufficient to mimic the morphine effects observed in the
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FIGURE 3 | Modulation of spinal reflex amplitudes (SRAs) by
morphine. (A1) Example of a reflex response recorded from ventral roots
(10 consecutive sweeps superimposed). Stimulation of a dorsal root (at
stimulus artifact) induced a monosynaptic reflex response (MSR) in the
corresponding ventral root. The boxed region identifies the epochs chosen
to calculate the amplitude of the spinal reflex amplitude (SRA) represented
in (A2). (A2) The rectification and subsequent integration of the epochs
identified in (A1) led to the signal values highlighted in the boxed region.
The final maximal values of each epoch were used as a measurement of
the SRA for each sweep, and used in the subsequent analysis steps
represented in panels (B,C), and Figures 4, 5. (B1) Typical time course of
control SRAs in WT before and during bath-application of 1μM morphine
(control: black symbols; morphine: white symbols). During morphine, reflex
amplitudes gradually decreased in amplitude. (B2) Normalized SRAs in WT
(n = 6). Morphine led to a significant reduction in SRA. ∗p = 0.004. (C1)
Typical time course of control SRAs in D3KO before and during
bath-application of 1μM morphine (control: black symbols; morphine: white
symbols). (C2) Normalized SRAs in D3KO (n = 12). In these animals,
morphine had no significant effect on SRA.
D3KO both in vivo and in vitro, we tested the consequence
of an acute block of the D3 receptor system in the isolated
spinal cord prior to morphine exposure (Figure 5). Following
baseline recordings, WT spinal cords were exposed to the D3
receptor-preferring antagonist, nafadotride (Figure 5A), before
FIGURE 4 | Modulation of spinal reflex amplitudes (SRAs) by the
MOR-preferring agonist, DAMGO. (A) In WT, DAMGO induced a
significant decrease in SRA (to 66.6 ± 4.5% of control, n = 15). WT:
∗p < 0.001. (B) In D3KO, DAMGO equally significant reduced SRA, albeit
to lesser degree than in WT (to 80.9 ± 3.4%, n = 8). D3KO: ∗p < 0.001.
The difference between DAMGO-induced effects in WT and D3KO was
significant (p = 0.013).
FIGURE 5 | Modulation of spinal reflex amplitudes (SRAs) by the
D3-receptor preferring antagonist, nafadotride. (A) In the isolated WT
spinal cord, bath-application of nafadotride led to slight, albeit insignificant
increase in SRAs (n = 8). (B) In the presence of nafadotride, additional
application of 1μM morphine failed to exert any modulatory action on SRAs
(n = 5).
additionally bath-applying morphine (Figure 5B). Application
of nafadotride alone (20μM) led to a slight, yet insignificant
increase in SRA from 99.7 ± 0.2 to 113.9 ± 11.1% (p = 0.87,
n = 8, Figure 5A). Subsequent application of morphine, in
the presence of nafadotride, and at the same dose that caused
the significant inhibition of SRAs under control conditions (cf.
Figure 3) failed to exert any significant modulatory action (ctrl:
99.8 ± 0.1 vs. 95.5 ± 3.9%, p = 0.69, n = 5, Figure 5B). These
data are testimony that an induced acute block of spinal D3
receptors is sufficient to prevent morphine effects.
D1 RECEPTOR EXPRESSION
As the D3 receptor is closely associated with the D1 receptor
through heterodimerization (Surmeier et al., 1996; Fiorentini
et al., 2008; Maggio et al., 2009; Missale et al., 2010; Cruz-Trujillo
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et al., 2013), we next tested if the dysfunction of the D3 recep-
tor system leads to changes in the D1 receptor system (Figure 6).
We found that in D3KO (n = 5), D1 receptor expression (49 kDa
band) increased significantly from 99.99 ± 4.6% (in WT) to
170.6 ± 8.9% (n = 5, p < 0.001). These data support the notion
that the increased excitability in the D3KO spinal cord could be,
at least in part, driven by an increased expression in D1 receptor
levels.
DISCUSSION
We show here that a dysfunction of the dopamine D3 receptor is
associated with a morphine-resistant state in vivo, that this behav-
ioral phenotype can be mimicked in the spinal cord in vitro, and
that this altered morphine responsiveness is associated with an
increase of pMOR but not total MOR expression in the lumbar
spinal cord. In addition, we found that an acute block of D3 recep-
tor function in the isolated spinal cord completely abolished the
modulatory capabilities of morphine on SRAs, suggesting that the
disruption of D3 receptor function in vitro is sufficient to induce
a state of morphine resistance.
TheD3 receptor is part of the D2-like family, and an evaluation
of D1- and D2 receptor agonists, at a time when other DA recep-
tors had not yet been described, reported that D2 activation pro-
duced antinociception, whereas D1 receptor activation induced
mild hyperalgesia (Rooney and Sewell, 1989). More recently it
was shown that co-administration of morphine with nafadotride
could effectively suppress the morphine-induced behavioral sen-
sitization observed in WT mice after acute morphine adminis-
tration (Li et al., 2010), and it was suggested that D3 receptors
regulate basal nociception (Li et al., 2012). Together, these data
support our findings that the D3 receptor may have a critical role
in regulating the morphine response in the spinal cord.
Loss of morphine analgesia is generally associated with a
reduction in functional MOR receptors, either through down-
regulation or desensitization of receptors (Williams et al., 2013).
Such a down-regulation is characterized by a decrease in func-
tional receptors present on the cell membrane due to degradation
or decreased biosynthesis (Finn and Whistler, 2001). We found
that D3KO and WT mice had similar levels of total MOR expres-
sion indicating that MOR receptor down-regulation per se is not
the primary mechanism behind the lack of morphine respon-
siveness in D3KO mice in vivo (Figure 2). Our studies, however,
were insensitive to receptor distribution between cellular com-
partments which would effect of the availability of functional
MOR. Desensitization involves molecular changes at the receptor
signaling level (Yu et al., 1997; Bohn et al., 2000), with recep-
tor phosphorylation being the first step. MOR desensitization is
under the control of GRK-mediated phosphorylation (Connor
et al., 2004; Gainetdinov et al., 2004; Garzon et al., 2005), fol-
lowed by ß-arrestin-mediated internalization (Bohn et al., 1999,
2000; Ohsawa et al., 2003; Connor et al., 2004). Our data show
that, while total MOR protein levels were similar across groups,
a greater proportion of those receptors were phosphorylated in
D3KO compared to WT, suggesting that these receptors were
desensitized and will not effectively signal, even in the presence
of a ligand (Figure 2). While the MOR can be phosphorylated
by both GPCR kinase (GRK) and non-GRK mechanisms, the
antibody used for this experiment was designed to recognize
phosphorylation of the Ser375 residue of the MOR, a site that is
critical for GRK phosphorylation, arrestin recruitment and endo-
cytosis (El Kouhen et al., 2001). This site has also been shown to
be phosphorylated in states of morphine tolerance and with sus-
tained release of β-endorphin, the endogenous ligand for MOR
(Petraschka et al., 2007). Such alterations in binding efficiency
of MOR to endogenous opioid ligands may provide one expla-
nation for our findings why D3KO mice have lower baseline
thermal pain thresholds than WT (Keeler et al., 2012), and they
may also explain the lack of analgesia with exogenous morphine
treatment. Studies assessing GRK activity levels and endogenous
opioid levels in D3KO mice are needed to determine if the base-
line phosphorylation of the MOR results from either increased
GRK activity and/or continuous activation due to an increased
availability of endogenous ligand.
A possible limitation of our immunohistochemical findings
is that the commercially-generated antibodies used in our study
were not, or only to a limited extent, validated in external peer
review processes, and thus may not be optimized or only partially
effective in detecting the proteins of interest (e.g., the 42 kDa band
we observed exclusively in the D3KO spinal cord when probing
for the D1 receptor, Figure 6). However, as the 49 kDa band (s.
arrows in Figure 6A) corresponds to the predicted D1 receptor
protein size, has together with a 75 kDa band also been observed
at this size recently (Mizuta et al., 2013), and was both present
and differentially expressed inWT and D3KO (Figure 6B), we are
confident that future work will corroborate themolecular changes
reported in this study. At the same time, given the high struc-
tural homology between D1 and D5 receptors, we can not exclude
the possibility that such studies may identify an up-regulation
of the D5 receptor instead of the D1 receptor as suggested by
our findings. Yet, given the similar functional properties of D1
and D5 receptors, both of which primarily mediate excitatory
actions, and the lack of evidence of D1/D5 receptor interactions,
we have based our model on the existing literature that has iden-
tified D1/D3 interaction and heterodimers, which could act in
synergistic fashion to control and mediate DA and morphine
actions.
Our finding that theMOR agonist DAMGO can induce amod-
ulatory response in both WT and D3KO could be the result of its
higher specificity in activating the MOR than morphine (Minami
et al., 1995; Onogi et al., 1995; Saidak et al., 2006), which also acti-
vate ∂-receptors (Walwyn et al., 2009), and/or its high affinity to
the MOR (Pak et al., 1996). As we observed lower levels of non-
p-MOR in D3KO than in WT (Figure 2), it is conceivable that
DAMGO but not morphine may be able to activate this receptor
population in D3KO, thus allowing the modulation of the SRAs
in vitro.
Resistance to opioid treatment involves in part the DA system,
including the D3 receptor system (Richtand et al., 2001; Sokoloff
et al., 2001; Kosten et al., 2002; Vorel et al., 2002; Le Foll et al.,
2007; Heidbreder, 2008; Hell, 2009; Li et al., 2012). Such tol-
erance can arise from a dysfunction of MOR and DA receptor
mediated cAMP/PKA second messenger pathways in the brain
(Zhao et al., 2007; Barraud et al., 2010). Both DA and MORs
are located pre- and post-synaptically in spinal cord sensory
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neurons (Xie et al., 1998; Levant and McCarson, 2001; Abbadie
et al., 2002; Millan, 2002) and they control the activation of
adenylyl-cyclase (AC). Generally, DA D1-like receptors (D1, D5)
mediate excitatory actions by increasing AC activation and rais-
ing cAMP levels in the target neuron (Missale et al., 1998; Neve
et al., 2004), whereas D2-like (D2, D3, and D4) and MOR path-
ways reduce AC activation and decrease cAMP levels (Yu et al.,
1990; Jaber et al., 1996; Mamiya et al., 2001; Neve et al., 2004;
Sheng et al., 2009). As D1 and D3 receptors often co-localize
or form heterodimers (Karasinska et al., 2005; Fiorentini et al.,
2008, 2010; Marcellino et al., 2008; Beaulieu and Gainetdinov,
2011) and oppositely regulate cAMP/PKA-mediated second mes-
senger pathways, it is conceivable that the dysfunction of the D3
receptor might directly modify D1 receptor function. While we
previously did not observe differences in D1 mRNA expression in
the D3KO spinal cord (Zhu et al., 2008), probing for the affiliated
protein expression revealed a significantly increased D1 receptor
protein expression in D3KO (Figure 6), supporting the notion
of a D3-mediated influence on D1 function. Additionally, the
similarities in MOR- and D3-mediated second messenger path-
ways suggest that they may have synergistic effects on reducing
pain transmission (Li et al., 2012; Saghaei et al., 2012), and the
co-localization of D1 with D3 receptors suggest that interac-
tions in their common cAMP/PKA signaling cascade might play
a role in the emergence of the morphine resistance seen in D3KO
(Figure 7).
In WT, a nociceptive stimulus induces the release of DA and
endogenous opioids, including beta-endorphin, which prefer-
entially bind the D3 and MOR, respectively, and initiate sig-
naling cascades that inhibit cAMP production, resulting in the
FIGURE 6 | Protein expression levels of the dopamine D1 receptor in
lumbar spinal cord. (A) ß-actin (top panels, red), D1R (middle panels,
green), and merged images of the 37–50 kDa band of interest (bottom
panels) of the same blot. Note that ß-actin expression is similar in WT and
D3KO. In contrast, the D1R antibody recognizes a strong signal at the 42 kDa
band that is present only in D3KO, and a weaker signal at the predicted band
size of 49 kDa that is differently expressed in WT and D3KO (arrows) and that
was used for the subsequent analysis. (B) The quantification of the 49 kDa
expression labeling, normalized to ß-actin expression, revealed a significant
increase in D1 receptor protein expression levels in D3KO (∗p < 0.001).
FIGURE 7 | Proposed model of D1 and D3 receptor interactions with MOR in WT (A) and D3KO (B). (A) Naïve WT with intact D1, D3, and MOR signaling
pathways. (B) D3KO with compromised D3 function and altered second messenger cascades.
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opening of K + channels or closing of Ca2+ channels (Connor
and Christie, 1999; Connor et al., 1999; Williams et al., 2001)
thus decreasing the transmission of the nociceptive signal. MOR
binding is followed by GRK-mediated phosphorylation (Connor
et al., 2004; Gainetdinov et al., 2004; Garzon et al., 2005), and
ß-arrestin-mediated internalization (Bohn et al., 1999, 2000;
Ohsawa et al., 2003; Connor et al., 2004) of the receptor, followed
by recycling or de-phosphorylation and subsequent reinsertion
into the membrane. More recent evidence also demonstrates that
recovery from phosphorylation and desensitization can occur
on the cell membrane, without the need for endocytosis of the
receptor (Arttamangkul et al., 2006; Doll et al., 2011).
This intracellular overlap between the MOR and DA systems,
along with evidence that D1, but not D2 receptors are involved
in mediating the behavioral responses to morphine by acting to
recruit GRK and ß-arrestin to the MOR (Urs et al., 2011) and
that blocking ß-arrestin expression has been shown to enhance
morphine-mediated analgesia (Li et al., 2009), has led to the
model proposed in Figure 7. According to our model, activation
of the D3 receptor leads in WT to a reduction of adenylate cyclase
(AC) activity, which will result in a reduction of cAMP levels
and decreased cAMP-mediated signaling, in a manner that is
synergistic to the MOR in response to its ligand. However, under
this scenario, D1 activation can also activate AC and compensate
for a D3- or MOR-mediated reduction in cAMP levels, thus
permitting a bi-directional modulation of cAMP-mediated
pathways. As D1 and D3 receptors often co-localize or form het-
erodimers in the brain (Karasinska et al., 2005; Fiorentini et al.,
2008, 2010; Marcellino et al., 2008; Beaulieu and Gainetdinov,
2011) and oppositely regulate cAMP/PKA-mediated second
messenger pathways, we postulate that, in D3KO, the dysfunction
of the D3 receptor prevents the D3-mediated block of AC, and
leaves D1 receptor actions unopposed. Under such circum-
stances, cAMP pathways might be continuously up-regulated,
and additional application of cAMP nucleotides might fail to
further increase cellular excitability. Further, activation of the
D1 receptor induces ß-arrestin signaling complex formation,
in which β-arrestin acts as a scaffold for different kinases and
phosphatases (Beaulieu et al., 2005; Urs et al., 2011) which in
turn may lead to desensitization of receptors through G protein-
independent signaling mechanisms (Pierce and Lefkowitz, 2001;
Lefkowitz and Shenoy, 2005) and increased pMOR levels. We
postulate that these changes to the second messenger systems,
either individually or in concert, can create the overly excitable
cellular state that is evidenced by decreased sensory thresholds
at baseline, and the resistance to the analgesic effects of the
opiates.
Taken together, our data reinforce the idea that changes in
the ability of opioids to provide analgesia can arise from a dys-
functional D3 receptor, as demonstrated using spinally-mediated
behaviors and reflex circuits, and that this unresponsiveness to
morphine can be induced acutely in the isolated spinal cord by
blocking the D3 receptor. Therefore, the D3KO mouse may be
a powerful tool with which to study the alterations to the MOR
second messenger-signaling cascade, to decipher the initial mech-
anisms that may underlie the waning of morphine effectiveness
over time.
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